50428-14-3

Basic information

• Product Name: 2,6-Ntp
• Synonyms: 2,6-Ntp;2,6-dimethyl-4-(2'-nitrosophenyl)-3,5-pyridinedicarboxylic acid dimethyl ester;2,6-DiMethyl-4-(2-nitrosophenyl)-3,5-pyridinedicarboxylic Acid 3,5-DiMethyl Ester 2,6-DiMethyl-3,5-dicarboMethoxy-4-(2-nitrosophenyl)pyridine;4-(2-Nitrosophenyl)-2,6-diMethyl-3,5-diMethoxycarbonylpyridine;Dimethyl 2,6-dimethyl-4-(2-nitrosophenyl)-3,5-pyridinedicarboxylate;Nifedipine Nitrosophenylpyridine Analog;dimethyl 2,6-dimethyl-4-(2-nitrosophenyl)pyridine-3,5-dicarboxylate;Nifedipine impurity B (EP)
• CAS NO: 50428-14-3
• Molecular Formula: C₁₇H₁₆N₂O₅
• Molecular Weight: 328.32
• Product Categories: Aromatics;Intermediates & Fine Chemicals;Metabolites & Impurities;Pharmaceuticals
• Mol File: 50428-14-3.mol
• Article Data: 23

Chemical Properties

• Melting Point: 93℃
• Boiling Point: 449°C at 760 mmHg
• Flash Point: 225.3°C
• Appearance: /
• Density: 1.26g/cm³
• Vapor Pressure: 2.97E-08mmHg at 25°C
• Refractive Index: 1.579
• PKA: 1.86±0.29(Predicted)
• CAS DataBase Reference: 2,6-Ntp(CAS DataBase Reference)
• NIST Chemistry Reference: 2,6-Ntp(50428-14-3)
• EPA Substance Registry System: 2,6-Ntp(50428-14-3)

Safety Data

• Hazard Codes: Xn
• Statements: 22-36/37/38
• Safety Statements: 26
• Hazardous Substances Data: 50428-14-3(Hazardous Substances Data)

Usage

Description

2,6-Ntp, also known as 2,6-dimethoxy-4-nitrophenol, is a photodegradation product of Nifedipine (N457000). It is an organic compound with a molecular formula of C8H9NO4 and a molecular weight of 183.16 g/mol. It possesses a yellow crystalline solid appearance and exhibits photochemical properties.

Uses

Used in Pharmaceutical Applications:
2,6-Ntp is used as a vasorelaxant agent for the treatment of cardiovascular diseases. It has been shown to relax contractions of the rat aortic strip induced by norepinephrine and other agonists, making it a potential candidate for the management of hypertension and other related conditions.
Used in Research and Development:
2,6-Ntp is utilized as a research compound in the study of photodegradation processes and the development of new pharmaceutical agents. Its photochemical properties and effects on vascular relaxation provide valuable insights into the design and synthesis of novel therapeutic agents with improved efficacy and safety profiles.

InChI:InChI=1/C17H16N2O5/c1-9-13(16(20)23-3)15(11-7-5-6-8-12(11)19-22)14(10(2)18-9)17(21)24-4/h5-8H,1-4H3

Upstream product

• 21829-25-4 nifedipine 
• 43114-08-5 methyl 1-(ethoxymethyl)-2,6-dimethyl-4-(2'-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate 
• 105-45-3 acetoacetic acid methyl ester 
• 552-89-6 2-nitro-benzaldehyde 
• 21731-17-9 methyl 3-aminocrotonate 
• 119777-23-0 C₁₇H₁₈N₂O₆*C₄₂H₇₀O₃₅ 

Relevant articles and documents

Structural studies of calcium channel blockers used in the treatment of hypertension - 1H and 13C NMR characteristics of nifedipine analogues

-

Formation of substituted 6-hydroxy-5-oxo-5,6-dihydrobenzo[c][2,7] naphthyridine upon photochemical transformation of nifedipine

Long-term exposure of nifedipine to daylight in ethanol gives 2,2′-bis[3,5-bis(methoxycarbonyl)-2,6-dimethylpyridin-4-yl]azoxybenzene and 6-hydroxy-1-methoxycarbonyl-2,4-dimethyl-5-oxo-5,6-dihydrobenzo[c] [2,7]naphthyridine as the major products.

Newly discovered photodegradation products of nifedipine in hospital prescriptions

New photodegradation products of nifedipine (1) have been isolated. They were found in tablets dispensed in the pulverized form by hospitals. 1 decomposed concurrently into six components after storage of 30 days under exposure to normal room light. The main photoproduct was a nitroso derivative (2) and others were minor. Preparative thin-layer chromatography has been used to isolate the six photodegradation products. The chemical structures of these isolated compounds were identified or estimated by comparison with authentic samples and/or using UV, IR, 1H NMR, mass spectroscopy, melting point determination, and elementary analysis. From these analyses, it was found that 1 was converted into a cis-azoxy derivative (4), a trans-azoxy derivative (5), a N,N'-dioxide derivative (6) and a lactam derivative (7) in addition to 2 and a nitro derivative (3). Furthermore, it is proposed that 2 is mainly responsible for the formation of these new products (4-7) by photochemical condensation.

Mediation of iron uptake and release in erythroid cells by photodegradation products of nifedipine

The effects of five Ca2+ channel antagonists on iron uptake by erythroid cells were investigated using rabbit reticulocytes and erythrocytes, and transferrin-bound iron and non-transferrin-bound iron (Fe(II)). All of the antagonists except nife

The protection of nifedipin from photodegradation due to complex formation with β-cyclodextrin

The inclusion complex β-cyclodextrin:nifedipin was prepared in solid state by coprecipitation with 1:1 mol ratio. The structure of the obtained complex and nifedipin was characterized by use of X-ray diffraction (XR), infrared spectroscopy (FTIR), nuclear magnetic resonance (NMR), and differential scanning calorimetry (DSC) methods. The photodegradation of nifedipin and the β-cyclodextrin:nifedipin inclusion complex in solid state was monitored under natural daylight by infrared spectroscopy, whereby the free nifedipin degraded four to five times faster than the complexed nifedipin. The photodegradation products of both free and complexed nifedipin, formed during irradiation at 350 nm (with corresponding energy flux of 18 W m-2) were monitored by liquid chromatography during various time intervals. The speed of formation of nitroso- and nitro-phenyl derivatives by nifedipin irradiation was significantly higher than those of complexed nifedipin irradiation, which indicates its increased photostability in the inclusion complex. The effect on this property is significant because it contributes both to the improvement of the therapeutic effect of nifedipin and to the safer application thereof.

Nitro group photoreduction of 4-(2-nitrophenyl)- and 4-(3-nitrophenyl)-1,4- dihydropyridines

The photoprocesses of nifedipine, a 4-(2-nitrophenyl)-1,4-dihydropyridine, and nimodipine and nitrendipine, two 3-nitrophenyl Hantzsch-type analogues, were studied by steady-state and time-resolved methods. The intramolecular photoreduction of nifedipine

TREATMENT OF MCI AND ALZHEIMER'S DISEASE

The present invention provides, among other things, therapeutic compositions and methods that can effectively treat, slow or prevent a neurological disease (e.g., a neurodegenerative disease, e.g., mild cognitive impairment (MCI) or Alzheimer's disease (A